General MedicationsTOPICALGeneric

LOTRISONE

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

Standard Dose

EQ 0.05% BASE;1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Discontinued

Summary

Approval overview LOTRISONE is listed in Drugs@FDA under application 018827 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE Form and strength CREAM;TOPICAL - EQ 0.05% BASE;1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ORGANON Submission history Latest submission status date: 2019-06-14 00:00:00.

Structured Monograph

Clinical summary

Approval overview LOTRISONE is listed in Drugs@FDA under application 018827 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE Form and strength CREAM;TOPICAL - EQ 0.05% BASE;1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ORGANON Submission history Latest submission status date: 2019-06-14 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Discontinued
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.